Canadian Society Proteasome purification of Nephrology: No recommendation. European Best Practice Guidelines: No recommendation. Amsterdam Forum: Care of the live kidney donor There are no guidelines available for surgical technique in living donor nephrectomy. In relation to DVT prophylaxis, factor v-leiden, a variant of the coagulation

protein factor v, is associated with venous thrombosis, especially in oral contraceptive users. It is the most common hereditary blood coagulation disorder and is present in 3–8% of the healthy white population. Factor v-leiden mutant genes have been detected in 2% of living donors. The odds ratio of a venous thrombo-embolic event is 11 times greater in women taking oral contraceptives who have factor v-leiden mutation than those who do not. It is recommended that a history of venous thromboembolism be ascertained prior to an in-depth coagulation work-up. Unless the medical history reveals a medical concern that would necessitate a comprehensive coagulation profile, tests are considered not likely to yield information. Such tests include PT, PTT, antithrombin 3, protein S, Protein C, Activated protein C resistance (APC), PT- Prothrombin mutation, cardiolipin antibodies and lupus anticoagulants. It is recommended that oral contraceptives and hormone replacement therapy be withheld for 3 months

prior to donation. Transplant units performing live donor nephrectomy should be required to submit prospective audit data to a centralized, independently-maintained registry as the most feasible means of Trichostatin A identifying differences in major outcome measures of donor safety. Norma Gibbons and David Nicol have no relevant financial affiliations that would cause a conflict of interest according to the conflict of interest statement set down by CARI. “
“Aims:  Goodpasture’s syndrome, glomerulonephritis and pulmonary haemorrhage, may be due to a variety of causes. Rarely, patients with Goodpasture’s syndrome present with both anti-glomerular basement membrane (GBM) and antineutrophil cytoplasmic antibody (ANCA). The aim of this report was to determine the incidence, clinical features, management and

these outcomes of patients presenting with concurrent ANCA and anti-GBM disease in Auckland. Methods:  Potential patients were identified by an electronic search of serology for ANCA and anti-GBM antibody, diagnostic renal biopsy, or in-hospital admissions using ICD9 and ICD10 codes between 1998 and 2008. A retrospective case-note review of all potential cases was performed. Results:  Six cases were identified: two women and four men. The incidence was estimated at 0.47 cases per million people per year. The mean age of presentation was 59 years (range 25–85 years). One patient was a smoker and two patients were ex-smokers. All subjects were anaemic, had haemoptysis and an abnormal chest X-ray at presentation. The mean creatinine at presentation was 225 µmol/L (range 126–406 µmol/L); all patients had haematuria and proteinuria.